
## **NeuroNEXT Network**

## **Standard Operating Procedure (SOP)**


# Site Performance Monitoring Version 2.0 SOP NN SS 404

Originators: NeuroNEXT CCC and DCC Personnel

Reviewed and Approved by:



NN SS 404 Page 1 of 5



-DocuSigned by DIXIE ECKLUND



15-Feb-2023

-7006AF622EFC40B6A067A08EC02591B6

Name and Title: Dixie J. Ecklund, RN MSN MBA (DCC Associate Director)

#### Signature and Date:

\_\_\_DocuSigned by Stacey Grabert



Starry Grahert | I approve this document | 22-Feb-2023 | 11:25:58 AM EST

22-Feb-2023

-60CC52B0747A44E6B2208D8D880698C0

Name and Title: Stacey Grabert, Pharm.D, MS, (CCC Director of Quality Assurance)

#### **Signature and Date:**

-72C6AAFD8CC4485582ACA0700072901A

\_\_\_DocuSigned by Joan Ohayon



Joan Chayon | I approve this document | 15-Feb-2023 | 9:05:55 AM PST

15-Feb-2023

Name and Title: Joan Ohayon, RN, MSN, CRNP, MSCN (NINDS, NeuroNEXT Program Official)

**NN SS 404** Page **2** of **5** 

#### **NN SS 404**

## NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SITE PERFORMANCE MONITORING

#### 1. POLICY

The NeuroNEXT Clinical Coordinating Center (CCC) will work with the Data Coordinating Center (DCC) and Protocol Principal Investigator (PPI)/ Sponsor to monitor site performance at all Clinical Study Sites (CSS) participating in Network studies. The CCC will work with the DCC and PPI to create site performance goals and metrics for each Network study, and will ensure that these goals and metrics are communicated to each participating CSS. In instances where a CSS is not meeting performance goals or metrics, the CCC (in collaboration with the DCC and PPI) will assist the CSS in identifying root causes for performance issues. The CCC will work with the CSS to develop individual Corrective Action and Preventative Action (CAPA) plans and design more effective procedures to prevent similar issues in the future.

The CCC, DCC, and PPI will determine study-specific criteria for suspension and/or termination of CSS participation in a study for inadequate enrollment, non-compliance with the study protocol or Good Clinical Practice (GCP) principles, or other serious issues related to site performance.

#### 2. SCOPE

This SOP has been developed to be in alignment with federal regulations and Good Clinical Practices (GCP) as set forth in the 2016 Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). The policies and procedures described in this SOP apply to the NeuroNEXT CCC and DCC within the context of their oversight and advisory roles for the NeuroNEXT Network, and to all NeuroNEXT investigators, staff, subcontractors, or other entities associated with the NeuroNEXT Network who manage, oversee, and conduct research regulated by FDA and/or applicable review committees.

#### 3. ROLES AND RESPONSIBILITIES

The CCC, DCC, and PPI (or designee), will develop site performance metrics for each Network study

The CCC Project Manager (PM), and DCC Protocol Coordinator (PC) and monitors (or designee), are responsible for pro-actively identifying potential issues at each CSS. If issues are identified, the study team is responsible for working with the CSS to analyze the root cause of the issue and to develop a CAPA plan. The study team will notify the site support team as needed.

The CCC PM, in collaboration with the DCC PC and monitors and site support team, if needed are responsible for assisting each CSS with implementation of CAPA plans.

The CCC, DCC and PPI (or designee) are responsible for determining criteria for suspension and/or termination of CSS participation in a study.

The PPI or his/her designee, under the direction of/advice from the Protocol Steering Committee (PSC), is responsible for communicating any issues related to suspension or termination of CSS participation in a study, and for communicating any decisions regarding these matters to the CCC, the Single Institutional Review Board (SIRB), the DCC, the protocol study team, and the CSS.

The PSC is responsible for advising the PPI or his/her designee on issues related to suspension or termination of CSS participation in a study.

The DCC is responsible for performing study close-out visits, as needed.

#### 4. APPLICABLE REGULATIONS AND GUIDELINES

21 CFR 312.50	General Responsibilities of Sponsors
21 CFR 312.53	Selecting Investigators and Monitors
ICH E6, 2.7	The Principles of ICH GCP
ICH E6, 5.1	Quality Assurance and Quality Control

NN SS 404 Page 3 of 5

#### 5. REFERENCES TO OTHER APPLICABLE SOPS

NN SS 405 Study Close Out Visits

NN PM 501 Communication

NN SM 602 Single Institutional Review Board Reporting

#### 6. ATTACHMENTS AND REFERENCES

NN SS 404 – A Document History

#### 7. TERMS AND ABBREVIATIONS

The following terms and abbreviations are used in this document:

CAPA Corrective Action and Preventative Action plan

CCC Clinical Coordinating Center at Massachusetts General Hospital

CSS Clinical Study Site

DCC Data Coordinating Center at The University of Iowa

FDA U.S. Food and Drug Administration

GCP Good Clinical Practice

ICH International Conference on Harmonisation

PM Project Manager

PPI Protocol Principal Investigator
PSC Protocol Steering Committee

SIRB Single Institutional Review Board

#### 8. SPECIFIC PROCEDURES

#### A. Site Performance Monitoring

#	Who	Task	Attachment / References	Related SOP
1.	CCC, DCC, and PPI or designee	Develop site performance metrics for each study		
2.	CCC, DCC	Proactively identify site performance issues.		
3.	CCC, DCC, and PPI or designee	Perform root cause analysis and develop CAPA plans		
4.	CCC, DCC, and Site intervention team,	Work with CSS to implement CAPA plans		
5.	CCC, DCC, and PPI or designee	Determine criteria for suspension and/or termination of CSS participation in study		

#### A. Closing a Site For Cause

#	Who	Task	Attachment / References	Related SOP
1	PPI or designee	Discuss potential suspension and/or termination of CSS participation in study with PSC		

NN SS 404 Page 4 of 5

#	Who	Task	Attachment / References	Related SOP
2	PSC	Advise PPI on issues related to CSS suspension and or termination from participation in study		
3	PPI or designee	Communicate with CCC, SIRB, DCC and Protocol Study Team members regarding CSS suspension or termination from participation in study		NN PM 501 NN SM 602
4	PPI or designee	Communicate with CSS any decisions related to suspension or termination from participation in study		NN PM 501
5	DCC Monitors	Perform study close out visits, as needed		NN SS 405

NN SS 404 Page 5 of 5

### **DocuSign**

#### **Certificate Of Completion**

Envelope Id: 7AC2BAAAD3FC46D29219C5F41974B5BF

Subject: Complete with DocuSign: NN SS 404 Site Performance Monitoring v2.0.docx

Source Envelope:

AutoNav: Enabled

Document Pages: 5 Certificate Pages: 6 Signatures: 6 Initials: 0 Envelope Originator: Tania Leeder

Status: Completed

TLEEDER@PARTNERS.ORG IP Address: 73.123.188.5

EnvelopeId Stamping: Disabled

Time Zone: (UTC-05:00) Eastern Time (US & Canada)

#### **Record Tracking**

Status: Original

2/15/2023 8:15:52 AM

Holder: Tania Leeder

TLEEDER@PARTNERS.ORG

Location: DocuSign

#### **Signer Events**

**Christopher Coffey** 

christopher-coffey@uiowa.edu

Security Level: Email, Account Authentication

(Required), Login with SSO

#### **Signature**

Christopher Coffey

Signature Adoption: Pre-selected Style

Signature ID:

C68AC8DD-8033-4CF9-82AE-D1200765F147

Using IP Address: 128.255.113.139

With Signing Authentication via DocuSign password

With Signing Reasons (on each tab):

I approve this document

#### **Electronic Record and Signature Disclosure:**

Accepted: 2/15/2023 11:21:19 AM ID: 4183bf59-aa08-4144-ab4e-c75fa3fa1b2f


DIXIE ECKLUND

dixie-ecklund@uiowa.edu

Security Level: Email, Account Authentication

(Required), Login with SSO

— DocuSigned by DIXIE ECKLUND



I approve this document 15-Feb-2023 | 10:56:10 AM PST

-7006AF622EFC40B6A067A08EC02591B6

Signature Adoption: Drawn on Device

Signature ID:

7006AF62-2EFC-40B6-A067-A08EC02591B6

Using IP Address: 128.255.112.230

With Signing Authentication via DocuSign password

With Signing Reasons (on each tab):

I approve this document

#### **Electronic Record and Signature Disclosure:**

Accepted: 2/15/2023 1:53:47 PM

ID: 79427082-7dee-43d7-ad1a-0b6bcf9caaf6

#### **Timestamp**

Sent: 2/15/2023 8:18:52 AM Viewed: 2/15/2023 11:21:19 AM Signed: 2/15/2023 11:21:42 AM

Sent: 2/15/2023 8:18:52 AM Viewed: 2/15/2023 1:53:47 PM Signed: 2/15/2023 1:56:12 PM **Signer Events Signature Timestamp** Joan Ohayon Sent: 2/15/2023 8:18:54 AM Joan Oliayon ohayonj@ninds.nih.gov Viewed: 2/15/2023 12:05:39 PM Security Level: Email, Account Authentication Signed: 2/15/2023 12:05:58 PM (Required) Signature Adoption: Pre-selected Style Signature ID: 72C6AAFD-8CC4-4855-82AC-A0700072901A Using IP Address: 156.40.137.188 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document **Electronic Record and Signature Disclosure:** Accepted: 2/13/2023 2:03:22 PM ID: 385a0a53-0f0c-4395-88f6-d5700c36e050 Marianne Chase Sent: 2/15/2023 8:18:53 AM Marianne Chase MCHASE@mgh.harvard.edu Viewed: 2/15/2023 8:54:06 PM Sr Director, Clinical Trial Operations Signed: 2/15/2023 8:55:20 PM Insight OBO The Massachusetts General Hospital Signature Adoption: Pre-selected Style Security Level: Email, Account Authentication Signature ID: (Required) 58FE690F-6BCA-4F23-90E3-DA15BCE3F578 Using IP Address: 73.114.253.109 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document **Electronic Record and Signature Disclosure:** Not Offered via DocuSign -DocuSigned by Merit Cudkowicz Merit Cudkowicz Sent: 2/15/2023 8:18:53 AM cudkowicz.merit@mgh.harvard.edu Viewed: 2/17/2023 1:52:20 AM Merit Cudkowicz 17-Feb-2023 | 1:52:32 AM EST Signed: 2/17/2023 1:52:34 AM Chief of Neurology Security Level: Email, Account Authentication 9F8FE4180E504C6AB0A67B835E80C644 (Required), Logged in Signature Adoption: Pre-selected Style Signature ID: 9F8FE418-0E50-4C6A-B0A6-7B835E80C644 Using IP Address: 68.239.56.73 With Signing Authentication via DocuSign password With Signing Reasons (on each tab):

I approve this document

Electronic Record and Signature Disclosure: Accepted: 2/17/2023 1:52:20 AM

ID: aa60d283-8b84-4d84-ab65-0af5e78f7731

Signer Events	Signature	Timestamp
Stacey Grabert		Sent: 2/15/2023 8:18:54 AM
sgrabert@mgh.harvard.edu	Stacey Grabert	Viewed: 2/22/2023 11:25:48 AM
Director QA	•	Signed: 2/22/2023 11:26:01 AM
Stacey Grabert Security Level: Email, Account Authentication (Required)	Signature Adoption: Pre-selected Style Signature ID: 60CC52B0-747A-44E6-B220-8D8D880698C0 Using IP Address: 132.183.56.49	
	With Signing Authentication via DocuSign passwo	rd
Electronic Bernal and Oliverton Bioderon	With Signing Reasons (on each tab): I approve this document	

## Electronic Record and Signature Disclosure: Accepted: 7/20/2020 8:50:14 AM ID: 5ebadf74-e399-40fd-be82-9c7ca902061b

In Person Signer Events	Signature	Timestamp
Editor Delivery Events	Status	Timestamp
Agent Delivery Events	Status	Timestamp
Intermediary Delivery Events	Status	Timestamp
Certified Delivery Events	Status	Timestamp
Carbon Copy Events	Status	Timestamp
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent Certified Delivered Signing Complete Completed	Hashed/Encrypted Security Checked Security Checked Security Checked	2/15/2023 8:18:55 AM 2/22/2023 11:25:48 AM 2/22/2023 11:26:01 AM 2/22/2023 11:26:01 AM
Doumont Events	Status	Timestamps
Payment Events	Otatus	imootampo

#### ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Insight OBO The Massachusetts General Hospital (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

#### **Getting paper copies**

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

#### Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

#### Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

#### All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

#### How to contact Insight OBO The Massachusetts General Hospital:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: jhenrique@mgh.harvard.edu

#### To advise Insight OBO The Massachusetts General Hospital of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at jhenrique@mgh.harvard.edu and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

#### To request paper copies from Insight OBO The Massachusetts General Hospital

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to jhenrique@mgh.harvard.edu and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

#### To withdraw your consent with Insight OBO The Massachusetts General Hospital

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;

ii. send us an email to jhenrique@mgh.harvard.edu and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

#### Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <a href="https://support.docusign.com/guides/signer-guide-signing-system-requirements">https://support.docusign.com/guides/signer-guide-signing-system-requirements</a>.

#### Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Insight OBO The Massachusetts General Hospital as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Insight OBO The Massachusetts General Hospital during the course of your relationship with Insight OBO The Massachusetts General Hospital.